Bortezomib Booms For Stada As Russian Problem Remains
Turnaround Strategy Is In The Works In Russia
Executive Summary
With group sales rising by double digits in 2019, Stada says it has the firepower to accelerate investment not only in the firm’s own product development but also broadly into external co-development and product in-licensing, to support sustainability and long-term growth.
You may also be interested in...
Stada Adds To Consumer Business With Sanofi Deal
Stada has expanded its business with another acquisition in the consumer healthcare space, this time striking a deal with Sanofi for 16 brands across 13 European markets.
Stada Raises Sales And Earnings But Admits ‘Tough’ Q2
Privately-owned Stada provided little insight into the exact mechanics of its operations for the first six months of 2020 but nevertheless said it had enjoyed an “above-market sales and earnings increase.” However, a raft of one-off expenses bit into the German firm’s profitability.
Stada Will Continue To Invest To Drive Growth
After a 12-month period that has seen Stada make significant investments in generics, biosimilars and consumer healthcare, CEO Peter Goldschmidt tells Generics Bulletin that the firm does not intend to stop there, as it pursues both organic and inorganic growth opportunities.